We use cookies for a better user experience. Read our Privacy Policy

I Agree

Gene Therapy Market

Gene Therapy Market (Product: Instruments, Media, Sera, and Reagents; and End-user: Biotechnology Companies, Pharmaceutical Companies, Academic Institutes, and Research Institutes) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

Gene Therapy Market Outlook 2028

  • The global gene therapy market was valued at US$ 1.3 Bn in 2020
  • It is estimated to expand at a CAGR of 19.8% from 2021 to 2028
  • The global gene therapy market is expected to reach the value of US$ 5.3 Bn by the end of 2028

Analysts’ Viewpoint on Gene Therapy Market Scenario

Although COVID-19 vaccines using viral vectors, nucleic acids, and proteins are helping to improve patient outcomes, there is a need for conducting continuous safety and efficiency evaluations over a long time period. However, the high cost of gene therapy products is emerging as a major restraint for the gene therapy market. Hence, companies should target selective marketing strategies toward high-income groups to increase its acceptance, which holds potentials to eventually reduce its cost in the upcoming decade. In this way, gene therapy companies can recover their costs for R&D investments. Different gene therapy approaches are being studied in the fields of oncology such as gene therapy-based immune modulation, anti-angiogenic gene therapy, oncolytic virotherapy, and the likes.

Role of FDA Critical for R&D in New Gene Therapy Candidates

Gene therapy is being publicized as an important treatment alternative, as it helps to eliminate the usage of surgery, drugs, or other procedures, which can have side effects. Mergers and acquisitions (M&A) in the gene therapy market is helping stakeholders to boost R&D in neurological gene therapy products in order to treat infants with spinal muscular atrophy (SMA) type 1 (SMA1).

Companies in the gene therapy market are striving to acquire the U.S. FDA’s (Food and Drug Administration) approval for CAR-T cell therapy products for use in the treatment of appropriate R/R (relapsed or refractory) patients with large B-cell lymphoma. New gene therapy candidates hold potentials to receive the rare pediatric disease designation as well as approval for use in the treatment of metachromatic leukodystrophy from the FDA.

To know the scope of our report Get a Sample on Gene Therapy Market

New COVID-19 Wave in Shanghai Accelerating R&D in Vaccines Using Gene Therapy

Companies in the gene therapy market are under scrutiny for developing COVID-19 vaccines using different technologies that are classified into four groups (nucleic acids, intact target viruses, proteins and viral vectors). New wave of Coronavirus in Shanghai, China is compelling biotechnology companies and research institutes to continuously run their R&D activities for the introduction of better treatment options.

High chances of moderate and severe symptoms with pneumonia due to the novel coronavirus is compelling academic institutes to increase research for the development of RNA vaccines and adenovirus vector vaccines that have been urgently approved.

Get a glimpse of the in-depth analysis through our Report Brochure

Selective Marketing Holds Potentials to Increase Acceptance for High Cost Gene Therapies

Despite several advantages, gene therapy is a highly expensive treatment alternative, which is depriving people from underdeveloped countries of Africa and developing economies of India to opt for it, thus impeding growth of the gene therapy market. High cost of gene therapy and limited reimbursement packages tend to deter patients from availing the treatment. Such findings are restraining gene therapy companies from meeting their expected revenue targets.

It has been found that gene therapy products for the treatment of retinal dystrophy is priced approximately US$ 8,50,000 per treatment, making it the world’s most expensive gene therapy. Since gene therapy products undergo high R&D investment, companies in the gene therapy market should selectively target patients from high income groups to increase its acceptance. They should conduct surveys and develop focus groups to gain insights about individual preferences for gene therapy products.

Expanding operations in future? To get the perfect launch ask for a custom report

Availability of Gene Therapy Treatment Centers Helps Increase Clinical Numbers

An uptick in success rates with gene therapy and new gene therapy product approvals have led to an increased demand for more number of treatment centers in the U.S. and Europe. After initial success rates of gene therapy, companies in the gene therapy market strive to increase the number of treatment centers in order to gain access to a large patient pool requiring gene therapy treatments.

The gene therapy product which has been approved for the treatment of patients up to the age of 25 years affected with large B-cell lymphoma, has only 41 treatment centers in the U.S., which limits a large number of patients from receiving gene therapy treatment. Hence, investment in treatment centers is necessary to increase clinical numbers.

Next-gen Gene Therapy Products Meet Requirements for Rare Diseases

Commercialization of gene therapy products in different areas of unmet medical needs to gain the first mover advantage and increasing competition among the leading biopharmaceutical companies to approve the products is expected to boost growth in the gene therapy market during the forecast period.

Next-gen gene therapy products are receiving marketing approval for the treatment of patients with a very rare disease called ADA-SCID (Severe Combined Immunodeficiency, due to Adenosine Deaminase deficiency). Strimvelis is the first ex-vivo stem cell gene therapy to be approved in Europe for the treatment of ADA-SCID.

Gene Therapy Market: Overview

  • According to Transparency Market Research’s latest report on the global gene therapy market for the historical period 2017–2019 and forecast period 2021–2028, promising therapeutic outcomes, new product approvals & commercialization, high prevalence, and increase in incidence of cancer are projected to drive the global gene therapy market during the forecast period

New Product Approvals & Commercialization: Major Driver

  • Increase in competition among the leading biopharmaceutical companies to approve and commercialize gene therapy products in different areas of unmet medical needs to gain the first mover advantage is expected to boost the growth of the gene therapy market during the forecast period
  • For instance, in May 2016, GlaxoSmithKline's gene therapy product, Strimvelis, received marketing approval for the treatment of patients with a very rare disease called ADA-SCID (Severe Combined Immunodeficiency, due to Adenosine Deaminase deficiency). Strimvelis is the first ex-vivo stem cell gene therapy to be approved in Europe for the treatment of ADA-SCID.
  • In August 2017, the U.S. FDA approved Novartis AG’s flagship gene therapy product Kymriah for the treatment of children and adults up to the age of 25 years affected with B-cell precursor acute lymphoblastic leukemia (ALL)

High Prevalence and Increase in Incidence of Cancer: Key Driver

  • High prevalence and increase in incidence rate of different types of cancers for which complete cure has not been developed is a key factor expected to drive the global gene therapy market during the forecast period
  • Diffuse large B-cell lymphoma (DLBCL), a type of white blood cell cancer, is a highly common aggressive form of non-Hodgkin lymphoma in adults. DLBCL affects around 7-8 cases per 100,000 population in the U.S. and the U.K. In the U.S., every year, around 7,500 patients are eligible for the treatment CAR-T cell therapy. DLBCL accounts for around 40% of all non-Hodgkin Lymphoma cases globally.
  • Gene therapy products Yescarta and Kymriah have been approved for the treatment of diffuse large B-cell lymphoma (DLBCL) and acute lymphoblastic leukemia (ALL), respectively

High Cost of Gene Therapy and Limited Reimbursement to Hamper Global Market

  • Gene therapy is a highly expensive treatment available in the world. High cost of gene therapy and limited reimbursement deter patients from availing treatment. Consequently, gene therapy companies have not generated the expected revenue.
  • For instance, Spark Therapeutics Inc.'s gene therapy product Luxturna, for the treatment of retinal dystrophy, is priced US$ 8,50,000 per treatment, making it the world’s most expensive gene therapy.
  • High price of gene therapy products is creating challenges for payers to make up front payment to these companies. However, biopharmaceutical companies, payers, and government institutions are working together to develop different pricing models for the reimbursement of gene therapy products.

Gene Therapy Market: Competition Landscape

  • This report profiles major players in the global gene therapy market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global gene therapy market is consolidated, with the presence of five major global players
  • Leading players operating in the global gene therapy market are
    • Novartis AG
    • Orchard Therapeutics Limited
    • Celgene Corporation
    • Spark Therapeutics, Inc.
    • Gilead Sciences, Inc.
    • Sibiono GeneTech Co. Ltd., among others

Gene Therapy Market: Key Developments

  • Key players in the global gene therapy market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global gene therapy market. A few expansion strategies adopted by players operating in the global gene therapy market are:
    • In April 2018, Novartis AG announced to acquire AveXis Inc., an Illinois-based gene therapy developer, for US$ 8.7 Bn. The latter is a leading R&D company engaged in the development of neurological gene therapy products to treat infants with spinal muscular atrophy (SMA) type 1 (SMA1).
    • In May 2018, Novartis AG’s flagship CAR-T cell therapy product ‘Kymriah’ obtained the U.S. FDA’s second approval for use in the treatment of appropriate R/R patients with large B-cell lymphoma
    • In May 2018, Orchard Therapeutics Limited’s gene therapy candidate OTL-200 received the ‘rare pediatric disease’ designation as well as approval for use in the treatment of metachromatic leukodystrophy from the FDA
    • In March 2018, Celgene Corporation formed a strategic agreement with Bluebird Bio, Inc. for joint development of anti-BCMA CAR-T cell therapy bb2121 and its joint promotion in the U.S. market
  • The report on the global gene therapy market discussed individual strategies, followed by company profiles of manufacturers of gene therapy products. The competition landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global gene therapy market.

Gene Therapy Market Snapshot

Attribute

Detail

Market Size Value in 2020

US$ 1.3 Bn

Market Forecast Value in 2028

US$ 5.3 Bn

Growth Rate (CAGR)

19.8%

Forecast Period

2021–2028

Quantitative Units

US$ Bn for Value

Market Analysis

It includes cross segment analysis at global as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market player - Competition matrix (by tier and size of companies)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Product
    • Instruments
    • Media
    • Sera
    • Reagents
  • End-user
    • Biotechnology Companies
    • Pharmaceutical Companies
    • Academic Institutes
    • Research Institutes

Regions Covered

  • North America
  • Latin America
  • Europe
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Novartis AG
  • Orchard Therapeutics Limited.
  • Celgene Corporation
  • Spark Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • Sibiono GeneTech Co. Ltd.

Customization Scope

Available upon request

Pricing

Available upon request

Gene Therapy Market – Segmentation

Product
  • Instruments
  • Media
  • Sera
  • Reagents
End-user
  • Biotechnology Companies
  • Pharmaceutical Companies
  • Academic Institutes
  • Research Institutes
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Gene Therapy Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of gene therapy market?

Gene therapy market is expected to reach the value of US$ 5.3 Bn by the end of 2028

What is the anticipated CAGR of the gene therapy market in the forecast period?

Gene therapy market is estimated to expand at a CAGR of 19.8% from 2021 to 2028

What are the key driving factors for the growth of the gene therapy market?

Gene therapy market is driven by high prevalence and increase in incidence rate of different types of cancers

Which region is expected to project the highest market share in the global gene therapy market?

Europe accounted for a major share of the global gene therapy market

Who are the key players in the global gene therapy market?

Key players in the global gene therapy market includes Novartis AG, Orchard Therapeutics Limited, Celgene Corporation, Spark Therapeutics, Inc.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Gene Therapy Market

4. Market Overview

    4.1. Introduction

        4.1.1. Segment Definition

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Gene Therapy Market Analysis and Forecast, 2018–2030

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Pipeline Analysis

    5.2. Regulatory Scenario by Region/globally

    5.3. Key Industry Events (Mergers, Acquisitions, Partnerships, etc.)

    5.4. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)

6. Global Gene Therapy Market Analysis and Forecast, by Product

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Product, 2018–2030

        6.3.1. Yescarta

        6.3.2. Kymriah

        6.3.3. Luxturna

        6.3.4. Strimvelis

        6.3.5. Gendicine

        6.3.6. Others

    6.4. Market Attractiveness Analysis, by Product

7. Global Gene Therapy Market Analysis and Forecast, by Application

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Application, 2018–2030

        7.3.1. Ophthalmology

        7.3.2. Oncology

        7.3.3. Adenosine Deaminase‐Deficient Severe Combined Immunodeficiency (ADA-SCID)

    7.4. Market Attractiveness Analysis, by Application

8. Global Gene Therapy Market Analysis and Forecast, by Region

    8.1. Key Findings

    8.2. Market Value Forecast, by Region

        8.2.1. North America

        8.2.2. Europe

        8.2.3. Asia Pacific

        8.2.4. Latin America

        8.2.5. Middle East & Africa

    8.3. Market Attractiveness Analysis, by Region

9. North America Global Gene Therapy Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. Market Value Forecast, by Product, 2018–2030

        9.2.1. Yescarta

        9.2.2. Kymriah

        9.2.3. Luxturna

        9.2.4. Strimvelis

        9.2.5. Gendicine

        9.2.6. Others

    9.3. Market Value Forecast, by Application, 2018–2030

        9.3.1. Ophthalmology

        9.3.2. Oncology

        9.3.3. Adenosine Deaminase‐Deficient Severe Combined Immunodeficiency (ADA-SCID)

    9.4. Market Value Forecast, by Country, 2018–2030

        9.4.1. U.S.

        9.4.2. Canada

    9.5. Market Attractiveness Analysis

        9.5.1. By Product

        9.5.2. By Application

        9.5.3. By Country

10. Europe Global Gene Therapy Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Product, 2018–2030

        10.2.1. Yescarta

        10.2.2. Kymriah

        10.2.3. Luxturna

        10.2.4. Strimvelis

        10.2.5. Gendicine

        10.2.6. Others

    10.3. Market Value Forecast, by Application, 2018–2030

        10.3.1. Ophthalmology

        10.3.2. Oncology

        10.3.3. Adenosine Deaminase‐Deficient Severe Combined Immunodeficiency (ADA-SCID)

    10.4. Market Value Forecast, by Country, 2018–2030

        10.4.1. Germany

        10.4.2. U.K.

        10.4.3. France

        10.4.4. Spain

        10.4.5. Italy

        10.4.6. Rest of Europe

    10.5. Market Attractiveness Analysis

        10.5.1. By Product

        10.5.2. By Application

        10.5.3. By Country

11. Asia Pacific Global Gene Therapy Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Product, 2018–2030

        11.2.1. Yescarta

        11.2.2. Kymriah

        11.2.3. Luxturna

        11.2.4. Strimvelis

        11.2.5. Gendicine

        11.2.6. Others

    11.3. Market Value Forecast, by Application, 2018–2030

        11.3.1. Ophthalmology

        11.3.2. Oncology

        11.3.3. Adenosine Deaminase‐Deficient Severe Combined Immunodeficiency (ADA-SCID)

    11.4. Market Value Forecast, by Country, 2018–2030

        11.4.1. China

        11.4.2. Japan

        11.4.3. India

        11.4.4. Australia & New Zealand

        11.4.5. Rest of Asia Pacific

    11.5. Market Attractiveness Analysis

        11.5.1. By Product

        11.5.2. By Application

        11.5.3. By Country

12. Latin America Global Gene Therapy Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Product, 2018–2030

        12.2.1. Yescarta

        12.2.2. Kymriah

        12.2.3. Luxturna

        12.2.4. Strimvelis

        12.2.5. Gendicine

        12.2.6. Others

    12.3. Market Value Forecast, by Application, 2018–2030

        12.3.1. Ophthalmology

        12.3.2. Oncology

        12.3.3. Adenosine Deaminase‐Deficient Severe Combined Immunodeficiency (ADA-SCID)

    12.4. Market Value Forecast, by Country, 2018–2030

        12.4.1. Brazil

        12.4.2. Mexico

        12.4.3. Rest of Latin America

    12.5. Market Attractiveness Analysis

        12.5.1. By Product

        12.5.2. By Application

        12.5.3. By Country

13. Middle East & Africa Global Gene Therapy Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Product, 2018–2030

        13.2.1. Yescarta

        13.2.2. Kymriah

        13.2.3. Luxturna

        13.2.4. Strimvelis

        13.2.5. Gendicine

        13.2.6. Others

    13.3. Market Value Forecast, by Application, 2018–2030

        13.3.1. Ophthalmology

        13.3.2. Oncology

        13.3.3. Adenosine Deaminase‐Deficient Severe Combined Immunodeficiency (ADA-SCID)

    13.4. Market Value Forecast, by Country, 2018–2030

        13.4.1. GCC Countries

        13.4.2. South Africa

        13.4.3. Rest of Middle East & Africa

    13.5. Market Attractiveness Analysis

        13.5.1. By Product

        13.5.2. By Application

        13.5.3. By Country

14. Competition Landscape

    14.1. Market Player - Competition Matrix (by tier and size of companies)

    14.2. Company Profiles

        14.2.1. Novartis AG

            14.2.1.1. Company Overview (HQ, Business Segments, Employee Strengths)

            14.2.1.2. Financial Overview

            14.2.1.3. Product Portfolio

            14.2.1.4. SWOT Analysis

            14.2.1.5. Strategic Overview

        14.2.2. Orchard Therapeutics Limited

            14.2.2.1. Company Overview (HQ, Business Segments, Employee Strengths)

            14.2.2.2. Financial Overview

            14.2.2.3. Product Portfolio

            14.2.2.4. SWOT Analysis

            14.2.2.5. Strategic Overview

        14.2.3. Celgene Corporation

            14.2.3.1. Company Overview (HQ, Business Segments, Employee Strengths)

            14.2.3.2. Financial Overview

            14.2.3.3. Product Portfolio

            14.2.3.4. SWOT Analysis

            14.2.3.5. Strategic Overview

        14.2.4. Spark Therapeutics, Inc.

            14.2.4.1. Company Overview (HQ, Business Segments, Employee Strengths)

            14.2.4.2. Financial Overview

            14.2.4.3. Product Portfolio

            14.2.4.4. SWOT Analysis

            14.2.4.5. Strategic Overview

        14.2.5. Gilead Sciences, Inc.

            14.2.5.1. Company Overview (HQ, Business Segments, Employee Strengths)

            14.2.5.2. Financial Overview

            14.2.5.3. Product Portfolio

            14.2.5.4. SWOT Analysis

            14.2.5.5. Strategic Overview

        14.2.6. Sibiono GeneTech Co. Ltd.

            14.2.6.1. Company Overview (HQ, Business Segments, Employee Strengths)

            14.2.6.2. Financial Overview

            14.2.6.3. Product Portfolio

            14.2.6.4. SWOT Analysis

            14.2.6.5. Strategic Overview

        14.2.7. Other prominent players

            14.2.7.1. Company Overview (HQ, Business Segments, Employee Strengths)

            14.2.7.2. Financial Overview

            14.2.7.3. Product Portfolio

            14.2.7.4. SWOT Analysis

            14.2.7.5. Strategic Overview

List of Table

Table 01: Global Gene Therapy Market Value (US$ Mn) Forecast, by Product, 2017‒2028

Table 02: Global Gene Therapy Market Value (US$ Mn) Forecast, by Applications, 2017‒2028

Table 03: Global Gene Therapy Market Value (US$ Mn) Forecast, by Region, 2017‒2028

Table 04: North America Gene Therapy Market Value (US$ Mn) Forecast, by Product,2017‒2028

Table 05: North America Gene Therapy Market Value (US$ Mn) Forecast, by Applications, 2017‒2028

Table 06: North America Gene Therapy Market Value (US$ Mn) Forecast, by Country, 2017‒2028

Table 07: Europe Gene Therapy Market Value (US$ Mn) Forecast, by Product,2017‒2028

Table 08: Europe Gene Therapy Market Value (US$ Mn) Forecast, by Applications, 2017‒2028

Table 09: Europe Gene Therapy Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017‒2028

Table 10: Asia Pacific Gene Therapy Market Value (US$ Mn) Forecast, by Product,2017‒2028

Table 11: Asia Pacific Gene Therapy Market Value (US$ Mn) Forecast, by Applications, 2017‒2028

Table 12: Asia Pacific Gene Therapy Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017‒2028

Table 13: Latin America Gene Therapy Market Value (US$ Mn) Forecast, by Product, 2017-2031

Table 14: Latin America Gene Therapy Market Value (US$ Mn) Forecast, by Applications, 2017‒2028

Table 15: Latin America Gene Therapy Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017‒2028

Table 16: Middle East & Africa Gene Therapy Market Value (US$ Mn) Forecast, by Product, 2017-2031

Table 17: Middle East & Africa Gene Therapy Market Value (US$ Mn) Forecast, by Applications, 2017‒2028

Table 18: Middle East & Africa Gene Therapy Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017‒2028

List of Figure

Figure 01: Global Gene Therapy Market Value (US$ Mn) Forecast, 2017–2028

Figure 02: Gene Therapy Market Value Share, by Product, 2020

Figure 03: Gene Therapy Market Value Share, by Applications – Use, 2020

Figure 04: Global Gene Therapy Market Value Share Analysis, by Product, 2020 and 2028

Figure 05: Global Gene Therapy Market Attractiveness Analysis, by Product, 2017–2028

Figure 06: Global Gene Therapy Market Value (US$ Mn), by Yescarta, 2017–2028

Figure 07: Global Gene Therapy Market Value (US$ Mn), by Kymriah, 2017–2028

Figure 08: Global Gene Therapy Market Value (US$ Mn), by Luxturna, 2017–2028

Figure 09: Global Gene Therapy Market Value (US$ Mn), by Strimvelis, 2017–2028

Figure 10: Global Gene Therapy Market Value (US$ Mn), by Gendicine, 2017–2028

Figure 11: Global Gene Therapy Market Value Share Analysis, by Applications, 2020 and 2028

Figure 12: Global Gene Therapy Market Attractiveness Analysis, by Applications, 2017–2028

Figure 13: Global Gene Therapy Market Value (US$ Mn), by Ophthalmology, 2017–2028

Figure 14: Global Gene Therapy Market Value (US$ Mn), by Oncology, 2017–2028

Figure 15: Global Gene Therapy Market Value (US$ Mn), by Adenosine Deaminase‐Deficient Severe Combined Immunodeficiency (ADA-SCID), 2017–2028

Figure 16: Global Gene Therapy Market Value Share Analysis, by Region, 2020 and 2028

Figure 17: Global Gene Therapy Market Attractiveness Analysis, by Region, 2017–2028

Figure 18: North America Gene Therapy Market Value (US$ Mn) Forecast, 2017–2028

Figure 19: North America Gene Therapy Market Value Share Analysis, Product, 2020 and 2028

Figure 20: North America Gene Therapy Market Attractiveness Analysis, by Product, 2017–2028 

Figure 21: North America Gene Therapy Market Value Share Analysis, by Applications, 2020 and 2028

Figure 22: North America Gene Therapy Market Attractiveness Analysis, by Applications, 2017–2028

Figure 23: North America Gene Therapy Market Value Share Analysis, by Country, 2020 and 2028

Figure 24: North America Gene Therapy Market Attractiveness Analysis, by Country, 2017–2028

Figure 25: Europe Gene Therapy Market Value (US$ Mn) Forecast, 2017–2028

Figure 26: Europe Gene Therapy Market Value Share Analysis, by Product, 2020 and 2028

Figure 27: Europe Gene Therapy Market Attractiveness Analysis, by Product, 2017–2028 

Figure 28: Europe Gene Therapy Market Value Share Analysis, by Applications, 2020 and 2028

Figure 29: Europe Gene Therapy Market Attractiveness Analysis, by Applications, 2017–2028

Figure 30: Europe Gene Therapy Market Value Share Analysis, by Country/Sub-Region, 2020 and 2028

Figure 31: Europe Gene Therapy Market Attractiveness Analysis, by Country/Sub-Region, 2017–2028

Figure 32: Asia Pacific Gene Therapy Market Value (US$ Mn) Forecast, 2017–2028

Figure 33: Asia Pacific Gene Therapy Market Value Share Analysis, by Product, 2020 and 2028

Figure 34: Asia Pacific Gene Therapy Market Attractiveness Analysis, by Product, 2017–2028 

Figure 35: Asia Pacific Gene Therapy Market Value Share Analysis, by Applications , 2020 and 2028

Figure 36: Asia Pacific Gene Therapy Market Attractiveness Analysis, by Applications, 2017–2028

Figure 37: Asia Pacific Gene Therapy Market Value Share Analysis, by Country/Sub-Region, 2020 and 2028

Figure 38: Asia Pacific Gene Therapy Market Attractiveness Analysis, by Country/Sub-Region, 2017–2028

Figure 39: Latin America Gene Therapy Market Value (US$ Mn) Forecast, 2017–2028

Figure 40: Latin America Gene Therapy Market Value Share Analysis, by Product, 2020 and 2028

Figure 41: Latin America Gene Therapy Market Attractiveness Analysis, by Product, 2017–2028 

Figure 42: Latin America Gene Therapy Market Value Share Analysis, by Applications, 2020 and 2028

Figure 43: Latin America Gene Therapy Market Attractiveness Analysis, by Applications, 2017–2028

Figure 43: Latin America Gene Therapy Market Value Share Analysis, by Country/Sub-Region, 2020 and 2028

Figure 44: Latin America Gene Therapy Market Attractiveness Analysis, by Country/Sub-Region, 2017–2028

Figure 45: Middle East & Africa Gene Therapy Market Value (US$ Mn) Forecast, 2017–2028

Figure 46: Middle East & Africa Gene Therapy Market Value Share Analysis, by Product, 2020 and 2028

Figure 47: Middle East & Africa Gene Therapy Market Attractiveness Analysis, by Product, 2017–2028 

Figure 48: Middle East & Africa Gene Therapy Market Value Share Analysis, by Applications, 2020 and 2028

Figure 49: Middle East & Africa Gene Therapy Market Attractiveness Analysis, by Applications, 2017–2028

Figure 50: Middle East & Africa Gene Therapy Market Value Share Analysis, by Country/Sub-Region, 2020 and 2028

Figure 51: Middle East & Africa Gene Therapy Market Attractiveness Analysis, by Country/Sub-Region, 2017–2028

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

277

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved